| Action |
Target |
In addition to estrogen receptors, include androgen
receptors and thyroid receptors in the screening. Study
a test scheme enhanced by addition of pathway screening
based on the microarray technology to improve precision
and completeness.
|
-2007 |
Establish the guidelines and evaluation criteria for
each component of the screening system.
|
-2007 |
Continue screening tests for ranking substances which
have biologically plausible hormone-like activities
(including those at low doses) to revise the priority
list.
|
2002- |
Promote the following for clarification
of the low-dose issue:
- Studies for securing reproducibility of detection of
hormone-like actions by agents at low doses
- Studies for elucidation of mechanisms of action and
determination of evaluation criteria of endocrine
disruption by exposure at the highly sensitive fetal,
neonatal and adolescent periods
- Systematic and continuous information gathering on
reported action by low doses in highly sensitive
periods; studies for interpretation of research results
in terms of (i) threshold problem, (ii) non-linear
dose-response relationships, and (iii) additive
reactions.
- Studies on effects on the homeostatic regulatory
systems, i.e. immune, thyroid-CNS and behavioral systems
- Studies on genomic findings
|
-2007 |
Develope a method for the lifelong monitoring of
rodents, in order to take into account the genesis,
development, maturation, and aging of the neural,
endocrine, and immune network, which will be a part of
the definitive studies.
|
2003- |
Develop a comprehensive guideline for
criteria of evaluation of endocrine disruption.
|
2005- |
Conduct detailed studies on the listed substances to
predict their endocrine disrupting effects on humans.
|
2005- |
Evaluate risks based on results of the detailed studies
and actual exposure situation; specify substances to be
monitored as necessary.
|
2005- |
Gather information on more efficient, precise or
sensitive analytical procedures to enhance the Analysis
Guideline.
|
2005- |
Monitor exposure to suspected endocrine disruptors and
diseases possibly caused by the exposure.
|
2002- |
Promote large-scale epidemiologic studies chiefly on
Japanese populations involving collection and use of
biological samples.
|
2002- |
Continuing gathering, review and summarization of
epidemiologic research information; make the results
available to public with regular updates.
|
2002- |
Accumulate analytical data on suspected endocrine
disruptors in various biological samples (including cord
blood) from the same mothers.
|
2002- |
Elucidate expression of effects of endocrine disruptors
on the living body in the range of actual body burden.
|
-2007 |
Conduct continuing risk communication
and obtain feedbacks for its improvement.
|
2002- |
